Explore all the latest information in myeloproliferative neoplasms
, arranged by key congresses and meetings. Listed below are recently updated congresses and meetings.
Trial update of the MANIFEST study of CPI-0610 in patients with myelofibrosis from EHA 2020
MANIFEST (NCT02158858) is a phase II clinical trial of CPI-0610, a small molecule inhibitor of bromodomain...
Long-term safety analyses of momelotinib in patients with myelofibrosis
Momelotinib is a selective and orally available inhibitor of Janus kinase (JAK) 1, JAK2, and activin A type 1 receptor (ACVR1)...
Promising preclinical data on selective HDAC11 inhibition and MPN improvement
During the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (2019), Vasundhara Sharma presented...
Final phase II results of the SMAC mimetic LCL161 for intermediate/high-risk myelofibrosis
The efficacy and safety of the LCL161 was assessed in patients with relapsed or refractory MF of...
American Association of Cancer Research
American Society of Clinical Oncology
American Society of Hematology
European Hematology Association